# Clinical Benefits of Octreotide for Managing Persistent Gastrointestinal Fluid Loss in Malignant Small Bowel Obstruction: A Case Report and Literature Review

## TL;DR

Octreotide helped manage fluid loss and related complications in a cancer patient with a blocked bowel.

## Contribution

Demonstrates octreotide's effectiveness in managing malignant small bowel obstruction with persistent fluid loss.

## Key findings

- Octreotide effectively managed gastrointestinal fluid loss in a patient with metastatic colonic adenocarcinoma.
- Treatment improved acute kidney injury and metabolic alkalosis associated with the obstruction.
- Case highlights octreotide as a potential palliative option for inoperable bowel obstruction.

## Abstract

Malignant small bowel obstruction (mSBO) is a frequent complication in patients with gastrointestinal or gynecologic cancers. For those with inoperable cancers and persistent obstructive symptoms, symptom palliation with a percutaneous gastrostomy tube (PGT) may be required. However, excessive fluid loss from the PGT can lead to significant fluid, electrolyte, and acid-base imbalances. We present a case of a man with metastatic colonic adenocarcinoma who developed mSBO, acute kidney injury, and metabolic alkalosis, all of which were effectively managed with octreotide.